Gilead Sciences, Inc. (NASDAQ:Guild) am One of the best medical stocks in Goldman Sachs. On July 10, the company announced that it had a contract with Global Fund to fight AIDS, tuberculosis and malaria. Under this agreement, the company should be able to access the low -income and intermediate income countries twice a year.
Kurhan / SHUTTERSTOCK.com
This is the first time that prevention HIV medicine can be used in low -income and intermediate income countries, as in high -income countries. Gilead can use this drug to use this drug, and the non -profit organizations select the beneficiaries based on the HIV program that can be used in the place.
The FDA has approved the YEZTUGO of Gilead, an injection last two years. The approval is considered a significant victory of the company, and analysts argue that there is a possibility of financing the preparatory market. The price of the drug is currently $ 28,218 in a one -year shooting, and we are waiting to see if the company will benefit from non -profit organizations.
Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercials medicines in areas that do not need medical needs. Develop pharmaceuticals to prevent and treat diseases that threaten life, including HIV, viral hepatitis and cancer.
We recognize GILD’s potential as an investment, but certain AI stocks provide greater potential and reduce the risk of disadvantages. If you are looking for extremely undervalued AI stocks that can benefit from the tariffs of the Trump era and on -shore trends, see free reports. Best short -term AI stock.
Next Read: 11 best green energy penny stocks to buy now and According to billionaire, 10 most popular AI Penny shares.
Public: No. This article was originally published My rich monkey.
